Form 4: Fortress Biotech CEO Lindsay Rosenwald Acquires Additional Series A Preferred Stock

Fortress Biotech's CEO, Lindsay Rosenwald, acquired 5,000 shares of Series A Cumulative Perpetual Preferred Stock at a weighted average price of $7.3529 on July 8, 2024, bringing his total holdings to 117,500 shares.

Summary

• On July 8, 2024, Lindsay Rosenwald, the CEO, President, and Chairman of Fortress Biotech, acquired 5,000 shares of Series A Cumulative Perpetual Preferred Stock.
• The purchase was made at a weighted average price of $7.3529 per share.
• Following the transaction, Rosenwald's total holdings in Series A Cumulative Perpetual Preferred Stock amount to 117,500 shares.
• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities Exchange Commission staff, the Issuer, or a stockholder of the Issuer.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares is generally a good sign, but the document itself is simply a report of the transaction.

Positives

• The CEO's purchase of additional shares could be interpreted as a sign of confidence in the company's prospects.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's value and future performance. This purchase by the CEO may be seen as a positive signal.

Stakeholder Impact

• The CEO's purchase may positively influence shareholder sentiment.

Key Dates